Impact of the initial decline in estimated glomerular filtration rate on the risk of new‐onset atrial fibrillation and adverse cardiovascular and renal events in patients with type 2 diabetes treated with sodium‐glucose co‐transporter‐2 inhibitors-Reference-Cited by-同舟云学术

Impact of the initial decline in estimated glomerular filtration rate on the risk of new‐onset atrial fibrillation and adverse cardiovascular and renal events in patients with type 2 diabetes treated with sodium‐glucose co‐transporter‐2 inhibitors

Published:2021-06-13 Issue:9 Volume:23 Page:2077-2089
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Chan Yi‐Hsin¹²³^ORCID,Chen Shao‐Wei⁴⁵,Chao Tze‐Fan⁶⁷,Kao Yi‐Wei⁸,Huang Chien‐Ying¹,Chu Pao‐Hsien¹²^ORCID

Affiliation:

1. The Cardiovascular Department Chang Gung Memorial Hospital, Linkou Taoyuan Taiwan

2. College of Medicine Chang Gung University Taoyuan Taiwan

3. Microscopy Core Laboratory, Chang Gung Memorial Hospital, Linkou Taoyuan Taiwan

4. Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Chang Gung Memorial Hospital, Linkou Medical Center Chang Gung University Taoyuan City Taiwan

5. Center for Big Data Analytics and Statistics, Chang Gung Memorial Hospital Taoyuan Taiwan

6. Division of Cardiology, Department of Medicine Taipei Veterans General Hospital Taipei Taiwan

7. Institute of Clinical Medicine, Cardiovascular Research Center National Yang Ming Chiao Tung University Taipei Taiwan

8. Graduate Institute of Business Administration, College of Management Fu Jen Catholic University Taipei Taiwan

Funder

Chang Gung Memorial Hospital

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14446

Reference33 articles.

1. Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes

2. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

3. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

4. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

5. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early reduction in albuminuria is associated with a steeper ‘dip’ in initial estimated glomerular filtration rate but favourable long‐term kidney outcomes in people with diabetes receiving sodium‐glucose cotransporter‐2 inhibitors;Diabetes, Obesity and Metabolism;2024-07

2. Kidney outcomes with SGLT2is for type 2 diabetes patients: does background treatment with metformin or RASis matter?;Frontiers in Endocrinology;2024-06-27

3. Factors affecting the sodium‐glucose cotransporter 2 inhibitors‐related initial decline in glomerular filtration rate and its possible effect on kidney outcome in chronic kidney disease with type 2 diabetes: The Japan Chronic Kidney Disease Database;Diabetes, Obesity and Metabolism;2024-05-08

4. Initial eGFR Changes with SGLT2 Inhibitor in Patients With Type 2 Diabetes and Associations With the Risk of Abnormal Serum Potassium Level;Journal of the American Heart Association;2024-05-07

5. Abrupt Decline in Estimated Glomerular Filtration Rate after Initiating Sodium-Glucose Cotransporter 2 Inhibitors Predicts Clinical Outcomes: A Systematic Review and Meta-Analysis;Diabetes & Metabolism Journal;2024-03-31